The third study demonstrated an increasing trend in annual hypertension prevalence, though it followed the increasing trend observed over the 5 years prior to ETI start [ 71 ].
← all excerpts
The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.
1
—
—